Core Insights - Natera reported a revenue of $665.5 million for the quarter ended December 2025, reflecting a year-over-year increase of 39.8% [1] - The company's EPS was $0.35, a significant improvement from -$0.41 in the same quarter last year, indicating a positive turnaround [1] - The reported revenue exceeded the Zacks Consensus Estimate of $660.45 million by 0.76%, while the EPS surpassed the consensus estimate of -$0.46 by 175.43% [1] Financial Performance Metrics - The number of tests processed was 923,600, exceeding the average estimate of 903,207 from three analysts [4] - Licensing and other revenues reached $4.34 million, surpassing the estimated $2.32 million by four analysts, marking a 37.7% increase compared to the previous year [4] - Product revenues amounted to $661.16 million, exceeding the average estimate of $570.94 million from four analysts, also reflecting a 39.8% increase year-over-year [4] Stock Performance - Natera's shares have declined by 10.2% over the past month, contrasting with a 0.6% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]